The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone

A retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)

Silvia Govi, David Christie, Silvia Mappa, Emerenziana Marturano, Marta Bruno-Ventre, Carlo Messina, Elías A Gracia Medina, David Porter, John Radford, Dae Seog Heo, Yeon Park, Barbara Pro, Jayasingham Jayamohan, Nick Pavlakis, Emanuele Zucca, Mary Gospodarowicz, Andrés J M Ferreri

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Indolent lymphomas primarily involving the skeleton (iPBL) represent <1% of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international database of 499 patients with a histopathological diagnosis of non-Hodgkin lymphoma and skeleton involvement, and clinical features, management and prognosis were analyzed. Twenty-six (5%) patients had an iPBL. Ten patients had small lymphocytic lymphoma, 10 had follicular lymphoma and six had lymphoplasmacytic lymphoma. Eleven patients had limited stage and 15 had advanced disease. The overall response rate was 73% (95% confidence interval [CI] = 57-89%). Median follow-up was 58 months, and the 5- and 10-year progression-free survival (PFS) rates were 37 ± 10% and 25 ± 12%, respectively. Nine patients are alive, with 5- and 10-year overall survival (OS) rates of 46 ± 10% and 29 ± 11%, respectively. Patients with small lymphocytic lymphoma showed significantly better outcome than patients with follicular lymphoma. Performance status and stage of disease were independently associated with OS. The prognosis of patients with primary bone lymphoplasmacytic or follicular lymphoma was less favorable.

Original languageEnglish
Pages (from-to)1796-1799
Number of pages4
JournalLeukemia and Lymphoma
Volume55
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Lymphoma
Retrospective Studies
Bone and Bones
Follicular Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Skeleton
Survival Rate
Non-Hodgkin's Lymphoma
Disease-Free Survival
Databases
Confidence Intervals
Survival

Keywords

  • Follicular lymphoma
  • Indolent lymphoma
  • Lymphoplasmacytic lymphoma
  • Osteolymphoma
  • Primary bone lymphoma
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone : A retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). / Govi, Silvia; Christie, David; Mappa, Silvia; Marturano, Emerenziana; Bruno-Ventre, Marta; Messina, Carlo; Medina, Elías A Gracia; Porter, David; Radford, John; Heo, Dae Seog; Park, Yeon; Pro, Barbara; Jayamohan, Jayasingham; Pavlakis, Nick; Zucca, Emanuele; Gospodarowicz, Mary; Ferreri, Andrés J M.

In: Leukemia and Lymphoma, Vol. 55, No. 8, 2014, p. 1796-1799.

Research output: Contribution to journalArticle

Govi, S, Christie, D, Mappa, S, Marturano, E, Bruno-Ventre, M, Messina, C, Medina, EAG, Porter, D, Radford, J, Heo, DS, Park, Y, Pro, B, Jayamohan, J, Pavlakis, N, Zucca, E, Gospodarowicz, M & Ferreri, AJM 2014, 'The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: A retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)', Leukemia and Lymphoma, vol. 55, no. 8, pp. 1796-1799. https://doi.org/10.3109/10428194.2013.853298
Govi, Silvia ; Christie, David ; Mappa, Silvia ; Marturano, Emerenziana ; Bruno-Ventre, Marta ; Messina, Carlo ; Medina, Elías A Gracia ; Porter, David ; Radford, John ; Heo, Dae Seog ; Park, Yeon ; Pro, Barbara ; Jayamohan, Jayasingham ; Pavlakis, Nick ; Zucca, Emanuele ; Gospodarowicz, Mary ; Ferreri, Andrés J M. / The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone : A retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 8. pp. 1796-1799.
@article{40e83fc4247e4447aba732e0dfc58ddf,
title = "The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: A retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)",
abstract = "Indolent lymphomas primarily involving the skeleton (iPBL) represent <1{\%} of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international database of 499 patients with a histopathological diagnosis of non-Hodgkin lymphoma and skeleton involvement, and clinical features, management and prognosis were analyzed. Twenty-six (5{\%}) patients had an iPBL. Ten patients had small lymphocytic lymphoma, 10 had follicular lymphoma and six had lymphoplasmacytic lymphoma. Eleven patients had limited stage and 15 had advanced disease. The overall response rate was 73{\%} (95{\%} confidence interval [CI] = 57-89{\%}). Median follow-up was 58 months, and the 5- and 10-year progression-free survival (PFS) rates were 37 ± 10{\%} and 25 ± 12{\%}, respectively. Nine patients are alive, with 5- and 10-year overall survival (OS) rates of 46 ± 10{\%} and 29 ± 11{\%}, respectively. Patients with small lymphocytic lymphoma showed significantly better outcome than patients with follicular lymphoma. Performance status and stage of disease were independently associated with OS. The prognosis of patients with primary bone lymphoplasmacytic or follicular lymphoma was less favorable.",
keywords = "Follicular lymphoma, Indolent lymphoma, Lymphoplasmacytic lymphoma, Osteolymphoma, Primary bone lymphoma, Small lymphocytic lymphoma",
author = "Silvia Govi and David Christie and Silvia Mappa and Emerenziana Marturano and Marta Bruno-Ventre and Carlo Messina and Medina, {El{\'i}as A Gracia} and David Porter and John Radford and Heo, {Dae Seog} and Yeon Park and Barbara Pro and Jayasingham Jayamohan and Nick Pavlakis and Emanuele Zucca and Mary Gospodarowicz and Ferreri, {Andr{\'e}s J M}",
year = "2014",
doi = "10.3109/10428194.2013.853298",
language = "English",
volume = "55",
pages = "1796--1799",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone

T2 - A retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)

AU - Govi, Silvia

AU - Christie, David

AU - Mappa, Silvia

AU - Marturano, Emerenziana

AU - Bruno-Ventre, Marta

AU - Messina, Carlo

AU - Medina, Elías A Gracia

AU - Porter, David

AU - Radford, John

AU - Heo, Dae Seog

AU - Park, Yeon

AU - Pro, Barbara

AU - Jayamohan, Jayasingham

AU - Pavlakis, Nick

AU - Zucca, Emanuele

AU - Gospodarowicz, Mary

AU - Ferreri, Andrés J M

PY - 2014

Y1 - 2014

N2 - Indolent lymphomas primarily involving the skeleton (iPBL) represent <1% of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international database of 499 patients with a histopathological diagnosis of non-Hodgkin lymphoma and skeleton involvement, and clinical features, management and prognosis were analyzed. Twenty-six (5%) patients had an iPBL. Ten patients had small lymphocytic lymphoma, 10 had follicular lymphoma and six had lymphoplasmacytic lymphoma. Eleven patients had limited stage and 15 had advanced disease. The overall response rate was 73% (95% confidence interval [CI] = 57-89%). Median follow-up was 58 months, and the 5- and 10-year progression-free survival (PFS) rates were 37 ± 10% and 25 ± 12%, respectively. Nine patients are alive, with 5- and 10-year overall survival (OS) rates of 46 ± 10% and 29 ± 11%, respectively. Patients with small lymphocytic lymphoma showed significantly better outcome than patients with follicular lymphoma. Performance status and stage of disease were independently associated with OS. The prognosis of patients with primary bone lymphoplasmacytic or follicular lymphoma was less favorable.

AB - Indolent lymphomas primarily involving the skeleton (iPBL) represent <1% of all primary bone lymphomas. The management and prognosis have not been previously described. Patients with primary and secondary iPBL were selected from an international database of 499 patients with a histopathological diagnosis of non-Hodgkin lymphoma and skeleton involvement, and clinical features, management and prognosis were analyzed. Twenty-six (5%) patients had an iPBL. Ten patients had small lymphocytic lymphoma, 10 had follicular lymphoma and six had lymphoplasmacytic lymphoma. Eleven patients had limited stage and 15 had advanced disease. The overall response rate was 73% (95% confidence interval [CI] = 57-89%). Median follow-up was 58 months, and the 5- and 10-year progression-free survival (PFS) rates were 37 ± 10% and 25 ± 12%, respectively. Nine patients are alive, with 5- and 10-year overall survival (OS) rates of 46 ± 10% and 29 ± 11%, respectively. Patients with small lymphocytic lymphoma showed significantly better outcome than patients with follicular lymphoma. Performance status and stage of disease were independently associated with OS. The prognosis of patients with primary bone lymphoplasmacytic or follicular lymphoma was less favorable.

KW - Follicular lymphoma

KW - Indolent lymphoma

KW - Lymphoplasmacytic lymphoma

KW - Osteolymphoma

KW - Primary bone lymphoma

KW - Small lymphocytic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84904873195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904873195&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.853298

DO - 10.3109/10428194.2013.853298

M3 - Article

VL - 55

SP - 1796

EP - 1799

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -